Role of Pyridoxine in Alleviating Cardiovascular Diseases: A Brief Review
Micronutrients are class of dietary components which are highly essential for the optimal health, growth, and development. These nutrients can overcome birth defects, maternal impairment, and increased risk of death. According to 2017 statistics, around 2 billion people in the developing countries are affected by micronutrient deficiency. There are around 13 essential vitamins which are found in nature. Vitamin B is more important as it plays a vital role in maintaining good health and well-being. Among several existing forms, the native and active form of vitamin B6 is PLP (pyridoxal 5- phosphate). PLP is a co-factor for several biochemical reactions and plays an imperative role in synthesis of amino acids, carbohydrates and fatty acids. Vitamin B6 supplementation in RDA showed to be highly health promising in controlling several clinical alignments such as cardiovascular disease, diabetes, neurological disease, premenstrual syndrome, stroke, peripheral vascular disease, coronary artery disease, pellagra skin disease, ataxia, hyperacuosis, suppression of colon tumor genesis and hyper irritability. Recently, it has been reported that 43.8% people are suffering from cardiovascular disease followed by stroke (16.8%) and is also expected to reach up to1.1 trillion by the end of 2035. It has been found that vitamin B6 lowers Homocystein in blood, which damages the inner linings of arteries causing blood clots and thereby reducing the symptoms of cardiovascular diseases. In addition to it humans have to depend on dietary sources of vitamin B6 which are produced by plants, fungi and bacteria. The present review currently focuses on the action of Vitamin B6 in the management of cardiovascular diseases.
2) B vitamins and vitamin C. Understanding Nutrition.9th Edition. Wadsworth. Thomson Learning 2002:306-346.
3) Bailey RL, Gahche JJ, Lentino CV, Dwyer JT, Engel JS, Thomas PR, et al. Dietary supplement use in the United States, 2006. J Nutr 2011;141:261-6.
4) Balk, E.M., Raman, G., Tatsioni, A., Chung, M., Lau, J. and Rosenberg, I.H. (2007) Vitamin B6, B12, and folic acid supplementation and cognitive function: a systematic review of randomized trials. Arch. Intern. Med., 167, 21–30.
5) Caterina Tinelli, Antonella Di Pino, Elena Ficulle, Serena Marcelli and Marco Feligioni.(2019),Hyperhomocysteinemia as a Risk Factor and Potential Nutraceutical Target for Certain Pathologies, frontries in nutrition,6: 1-13
6) Cheng, C.H., Chang, S.J., Lee, B.J., Lin, K.L. and Huang, Y.C. (2006) Vitamin B6 supplementation increases immune responses in critically ill patients. Eur. J. Clin. Nutr., 60, 1207–1213.
7) Cui R, Iso H, Date C, Kikuchi S, Tamakoshi A, Japan Collaborative Cohort Study G. Dietary folate and vitamin B6 and B12 intake in relation to mortality from cardiovascular diseases: Japan collaborative cohort study. Stroke 2010;41:1285
8) Fitzpatrick, T.B. (2011) Vitamin B6 in plants: more than meets the eye. Adv. Bot. Res. 59, 1–38.
9) Fitzpatrick, T.B., Amrhein, N., Kappes, B., Macheroux, P., Tews, I. and Raschle, T. (2007) Two independent routes of de novo vitamin B6 biosynthesis: not that different after all. Biochem. J. 407, 1–13.
10) Fowler B, Therumsch(2005), Homocystein an independent risk factor for cardiovascular and thrombotic disease,62(9):641-6
11) Hankey GJ, Eikelboom JW. Homocysteine and stroke. Lancet. 2005; 365:194–196.
12) Havaux, M.; Ksas, B.; Szewczyk, A.; Rumeau, D.; Franck, F.; Caffarri, S.; Triantaphylidès, C. Vitamin B6 deficient plants display increased sensitivity to high light and photo-oxidative stress. BMC Plant Biol. 2009,9, 130.
13) Hellmann, H., and Mooney, S. (2010). Vitamin B6: a molecule for human health? Molecules 15, 442–459.
14) Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. J Am Med Assoc. 2002;288: 2015–2022
15) Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. J Am Med Assoc. 2002;288:2015–2022.
16) Homocysteine-lowering trials for prevention of cardiovascular events: A review of the design and power of the large randomized trials, American Heart Journal Volume 151, Number 2 B-Vitamin Treatment Trialists’ Collaboration 283-287
17) Huang YC, Lee MS, Wahlqvist ML. Prediction of all-cause mortality by B group vitamin status in the elderly. ClinNutr 2012;31:191e8.
18) Institute of Medicine. Food and Nutrition Board. Dietary Reference Intakes: Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. Washington, DC: National Academy Press; 1998.
19) Long-Gang Zhao , Xiao-Ou Shu , Hong-Lan Li ,Jing Gao, Li-Hua Han ,Jing Wang Jie, Fang , Yu-Tang Gao , Wei Zheng , Yong-Bing Xiang.2018. Prospective cohort studies of dietary vitamin B6 intake and risk ofcause-specific mortality.journalofClinical Nutrition, 1-8
20) Mackey A, Davis S, Gregory J. Vitamin B6. In: Shils M, Shike M, Ross A, Caballero B, Cousins R, eds. Modern Nutrition in Health and Disease. 10th ed. Baltimore, MD: Lippincott Williams & Wilkins; 2005.
21) Malouf, R. and Grimley Evans, J. (2003) The effect of vitamin B6 on cognition. Cochrane Database Syst. Rev., 4, CD004393
22) McCormick D. Vitamin B6. In: Bowman B, Russell R, eds. Present Knowledge in Nutrition. 9th ed. Washington, DC: International Life Sciences Institute; 2006.
23) Morris MS, Picciano MF, Jacques PF, Selhub J. Plasma pyridoxal 5’-phosphate in the US population: the National Health and Nutrition Examination Survey, 2003-2004. Am J ClinNutr 2008;87:1446-54.
24) Percudani, R., and Peracchi, A. (2003). A genomic overview of pyridoxal phosphate-dependent enzymes.EMBO Rep. 4, 850–854.
25) Saposnik G, Ray JG, Sheridan P, McQueen M, Lonn E; Heart Outcomes Prevention Evaluation 2 Investigators. Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial. Stroke. 2009;40:1365–1372. Whitney EN, Rolfes SR. The water soluble vitamins
26) Simonetta Friso, V. Lotto, R. Corrocher, and Sang Woon Choi.(2011). Vitamin B6 and Cardiovascular Disease. Chapter 14:265-291.
27) Schneider, G., Kack, H. and Lindqvist, Y. (2000) The manifold of vitamin B6 dependent enzymes. Struct. Fold Des., 8, R1–R6.
28) Spinneker, A., Sola, R., Lemmen, V., Castillo, M.J., Pietrzik, K. and Gonzalez-Gross, M. (2007) Vitamin B6 status, deficiency and its consequences–an overview. Nutr. Hosp., 22, 7–24.
29) Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, Tishler PV, Hennekens CH. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in us physicians. JAMA. 1992; 268:877–881.
30) Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ. 2002; 325:1202
31) XinzhiChen, ShangfengZhao, YangSong, YejieShi, RehanaLeak, and GuodongCao.(2015).Nicotinamidephosphoribosyltransferase and cerebral ischemia. Current Topics in Medicinal Chemistry. 15:21: 2211-2221